Skip to content
NXGL

NEXGEL, INC.

NEXGEL, INC. Q4 FY2024 earnings call

March 24, 2025 · fiscal period ended 2024-12

EPS · actual vs est

$-0.08 / $-0.10Beat +20.0%

Revenue · actual vs est

$3.0M / $2.7MBeat +11.6%
Ask about this call

Summary

Generated 2025-03-24

Management highlights

  • 2024 was a record year with revenue growth over 100% for the third consecutive year.
  • Q4 gross margin 37% affected by reclassification of Amazon sales commissions; EBITDA and adjusted EBITDA loss were $726,000 and $621,000.
  • Q4 net loss included $243,000 one-time inventory write-offs, with no future write-offs expected.
  • Contract manufacturing expanded with new customers like Cintas, and consumer products saw brand expansions and new product launches.
  • Partnership with STADA progressing well, with plans to launch more products in future quarters.
View in transcript ↓

Segment performance

For the fourth quarter of 2024, revenue totaled $3.04 million, an increase of 181% compared to Q4 2023. Full year 2024 revenue was $8.69 million, up 112% from 2023. Contract manufacturing played a key role, driven by increased demand from existing customers and new global corporations like Cintas and Owens & Minor. Consumer products saw strong expansion: Medagel to launch new offerings, Kenkoderm to double product portfolio, Silly George grew from $2M annual run rate to over $5M post-acquisition, and partnership with STADA progressing well with Histasolv exceeding projections.

View in transcript ↓

Guidance

  • Expect Q1 2025 revenue at least $2.75 million.
  • Anticipate 2025 revenue to be at least $13 million.
  • Aim to achieve positive EBITDA in 2025, with adjusted EBITDA expected to improve quickly excluding one-time event in Q4.
View in transcript ↓

Risks

  • Forward-looking statements subject to risks and uncertainties as per SEC regulations. One-time inventory write-offs in Q4 were a factor, but no future such write-offs expected.
View in transcript ↓

Q&A highlights

Q: On guidance and adjusted EBITDA, when do you expect to reach positive adjusted EBITDA?

A: Joe McGuire said adjusted EBITDA will improve quickly, with Q1 being traditionally weakest but still good, expecting to improve in Q2 with new customers.

Q: Could you provide more context on the pipeline of new customers and industry applications?

A: Adam Levy said they have four large opportunities in pipeline, with some taking longer due to iterations and testing, others like Innovative Optics can get to market quickly.

Q: When might product from Innovative Optics start selling if data is positive?

A: Adam Levy said if data is positive, they expect to start selling product around mid-year 2025.

Q: Updates on AbbVie Acoustic device launch?

A: Adam Levy said AbbVie will ship product in Q2 on initial orders, receiving orders in Q1 as per plan.

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS$-0.08$-0.10+20.0%$-0.19
Revenue$3.0M$2.7M+11.6%$1.1M

Transcript

March 24, 2025

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.